Borderline Ovarian Surface Epithelial-Stromal Tumor

A borderline ovarian surface epithelial-stromal tumour is a growth that starts in the surface lining cells of the ovary. The cells multiply more than normal and look a bit abnormal under a microscope. But they do not break into (invade) the tissue under them the way regular cancers do. Because there is no “destructive invasion,” these tumours act less aggressively than most ovarian cancers. Most people do well after surgery. Many are young and want to keep fertility, so doctors often use ovary-sparing surgery when it is safe. ecancer+1

A borderline ovarian surface epithelial-stromal tumor is an ovarian growth that looks abnormal under the microscope but does not invade nearby tissue the way typical cancers do. Doctors often call it a “low malignant potential” tumor because it behaves in a much less aggressive way than invasive ovarian cancer. Most people are diagnosed at an early stage, and long-term survival is excellent after proper surgery. These tumors arise from the ovary’s surface lining and come in several histologic types, most often serous or mucinous. Care is centered on surgery (sometimes fertility-sparing), careful staging by specialists, and structured follow-up. Chemotherapy is usually not needed and has not shown clear survival benefit for typical borderline disease. Cancer.gov+2PMC+2

Other names

Doctors use several names that mean almost the same thing:

• Borderline ovarian tumour (BOT) or borderline epithelial ovarian tumour

• Atypical proliferative tumour (APT) (describes the extra growth and mild atypia)

• Tumour of low malignant potential (LMP) (older term still used in some papers)

• Borderline ovarian surface epithelial-stromal tumour (WHO style wording)

All of these point to an epithelial ovarian tumour with cell crowding and atypia, without destructive stromal invasion. This “no invasion” rule is what separates borderline tumours from invasive ovarian cancer. ecancer

Types

Borderline tumours are grouped by how the cells look and which normal tissue they resemble:

1. Serous borderline tumour (SBT)
   The most common type. It often forms many small finger-like papillae. Some cases have tiny areas that look like very early invasion (called “microinvasion”), but still behave in a borderline way if true destructive invasion is absent. Rarely, there are peritoneal “implants,” which also need careful review by the pathologist. PMC

2. Mucinous borderline tumour (MBT)
   Filled with mucin (thick fluid). Two patterns are seen: intestinal-type (looks like gut lining) and endocervical-type/seromucinous-type (looks like the cervix or a mix of mucinous/serous features). These can become very large. ScienceDirect

3. Endometrioid borderline tumour
   Looks like the lining of the uterus (endometrium). It is often linked to endometriosis. annalsmedres.org

4. Seromucinous borderline tumour
   Shows both serous-type and mucinous-type features and is commonly associated with endometriosis. PMC

5. Clear cell borderline tumour (very rare)
   Cells look clear under the microscope. It can be associated with endometriosis. annalsmedres.org

6. Borderline Brenner tumour (rare)
   Made of transitional-type (urothelial-like) cells and can have papillary areas. PMC

Causes

Scientists do not know one single cause. Instead, several factors appear to raise or lower risk. Think of these as gentle pushes rather than yes/no causes.

1. Ovulation over many years
   More lifetime ovulations may expose the surface epithelium to repeated repair, which may allow abnormal growth to start.

2. Not having children (nulliparity)
   Fewer pregnancies usually means more ovulations across life.

3. Infertility
   Some studies link infertility itself to risk, separate from fertility drugs.

4. Fertility drugs (mixed data)
   Research is mixed. Some older reports suggested a link, others did not. If there is a link, the absolute risk is still small.

5. Endometriosis
   Strongly linked to endometrioid and seromucinous borderline tumours. Endometriosis gives a background of chronic inflammation and repair. PMC

6. Smoking (especially for mucinous type)
   Smoking is more often linked to mucinous epithelial tumours, including borderline mucinous lesions.

7. Family history of epithelial ovarian tumours
   A family history may raise general epithelial ovarian neoplasm risk, though classic hereditary genes (like BRCA1/2) are not a common driver for borderline tumours.

8. Hormonal factors (long uninterrupted estrogen exposure)
   Long menstrual years without pregnancy can mean more exposure and more ovulations.

9. Polycystic ovary syndrome (PCOS)
   Evidence is limited and mixed. If present with obesity and anovulation, it may change risk through hormonal pathways.

10. Obesity
    Obesity can alter estrogen levels and inflammation and may nudge risk upward.

11. Early first period (early menarche)
    More reproductive years can mean more ovulations.

12. Late menopause
    Same logic as above: more lifetime ovulations.

13. Short or irregular cycles without ovulation
    Complex effect; anovulatory cycles can lower ovulation count, but endocrine changes may still affect risk biology.

14. Prior benign mucinous or serous cystadenomas
    Some borderline tumours seem to arise from long-standing benign cysts through step-wise changes.

15. Chronic pelvic inflammation
    Long-term inflammation can increase cell turnover and the chance of mutations.

16. Environmental factors (uncertain)
    Data are inconsistent; no single chemical is clearly proven to cause BOT.

17. KRAS mutation (common in mucinous BOT)
    This is a molecular feature, not an exposure, but it shows that a genetic change in the tumour is part of the pathway. ScienceDirect

18. BRAF mutation (seen in serous BOT)
    Another driver mutation especially in serous borderline lesions. PMC

19. Low-grade serous pathway biology
    Borderline serous tumours belong to the “low-grade serous” pathway rather than the high-grade serous pathway. This helps explain their slower behavior. ecancer

20. Protective factor: combined oral contraceptives
    Birth-control pills lower the number of ovulations and appear to reduce risk of epithelial ovarian tumours in general (specific data for BOT are less robust, but biologically consistent).

(Note: The strongest, best-documented links for BOT subtypes are with endometriosis for endometrioid/seromucinous/clear cell spectrum and KRAS/BRAF pathway mutations for mucinous/serous borderline lesions.) ecancer+2PMC+2

Symptoms

Many people have no symptoms until the mass is big enough to notice. Symptoms are usually from size, pressure, or torsion, not from spread.

1. Bloating
   A feeling of fullness or swelling in the belly.

2. Abdominal or pelvic pain
   Dull ache or pressure. Sharp pain may mean torsion (twisting) or rupture.

3. A sense of heaviness
   The lower belly may feel heavy or uncomfortable.

4. Abdominal distension
   Clothes feel tight; the tummy looks bigger.

5. A palpable mass
   You or your clinician may feel a lump in the lower abdomen.

6. Early fullness with meals
   You get full quickly because the mass presses on the stomach.

7. Constipation
   Pressure on the bowel can slow movement.

8. Urinary frequency or urgency
   The mass can press on the bladder.

9. Menstrual changes
   Periods may be irregular (many other causes are also common).

10. Pelvic pressure with activity
    Discomfort during walking or exercise.

11. Pain during sex (dyspareunia)
    Deep penetration may press on the mass.

12. Back pain
    Referred pain from pelvic pressure.

13. Unexpected weight change
    Weight gain from the mass or weight loss from poor appetite.

14. Shortness of breath
    Rare; only when the mass is very large or there is fluid up to the chest.

15. Acute severe pain
    Red flag for torsion or rupture. Needs urgent care.

Diagnostic tests

Big picture: Imaging plus expert pathology make the diagnosis. Blood markers can help, but cannot tell benign vs borderline vs cancer on their own. Surgical removal and full lab review (including implants/washings if present) is the gold standard. ScienceDirect+1

A) Physical-exam–based tests (what the clinician does with hands/eyes)

1. General abdominal exam
   The doctor looks and feels for swelling, tenderness, and a mass. They check for fluid (ascites) by percussion and for any hernias or scars that change the plan.

2. Bimanual pelvic exam
   One hand in the vagina and one on the abdomen to feel the uterus and adnexa (ovaries/tubes). A mobile, cystic, non-tender adnexal mass is common in BOT.

3. Rectovaginal exam
   A finger in the rectum and vagina at the same time can better feel the space behind the uterus (cul-de-sac) for nodules or tenderness that might suggest implants or endometriosis.

4. Assessment of mass mobility and tenderness
   A freely mobile mass leans toward benign/borderline; fixed or very tender masses raise worry for complications.

5. Check for abdominal fluid (shifting dullness)
   Simple bedside percussion can suggest ascites, which is uncommon in BOT but can occur.

B) “Manual tests” (bedside maneuvers and simple point-of-care steps)

6. Pregnancy testing (urine β-hCG) before imaging
   Not a BOT test, but essential in people of child-bearing age so pregnancy-safe imaging is chosen and ectopic pregnancy is ruled out.

7. Pain-provocation during sonopalpation
   Gentle pressure with the ultrasound probe helps map tenderness and the relation of the mass to surrounding organs.

8. Valsalva maneuver during ultrasound
   Bearing down can show how the mass moves and may help distinguish bowel loops from true solid tissue.

9. Bedside assessment for torsion
   Sudden severe pain with a tender, enlarged ovary suggests torsion, which needs urgent surgery—regardless of BOT vs other diagnosis.

10. Pre-op anaesthetic evaluation (airway, vitals, ECG as needed)
    Not diagnostic of BOT itself, but part of safe surgical planning when a mass likely needs removal.

C) Lab and pathological tests (the key is pathology)

11. CA-125 blood test
    A protein that can be high in many pelvic conditions. It can be normal or mildly raised in BOT. It cannot alone tell benign vs borderline vs cancer, so doctors never rely on it by itself. ScienceDirect

12. HE4 blood test
    Another marker sometimes measured with CA-125. It improves risk models in some settings, but again is not used alone to label a mass as benign/borderline/cancer. ScienceDirect

13. CEA and CA19-9 (especially for mucinous masses)
    These can be higher with mucinous tumours and help think about a possible gastrointestinal source vs primary ovarian mucinous tumour, but results are not definitive.

14. Complete blood count and basic chemistry
    Check general health, anemia, infection, and organ function before any procedure.

15. Peritoneal washings (cytology) at surgery
    Saline is washed around the pelvis and then examined for cells. It helps stage the disease and look for implants.

16. Frozen section (intra-operative pathology)
    A quick microscopic check during surgery to guide the surgeon. It can suggest “borderline” vs “benign” vs “invasive,” but the final answer always comes from full permanent sections because borderline categories can be subtle. ecancer

17. Final histopathology (gold standard)
    The pathologist examines many slides to confirm no destructive stromal invasion, describe the subtype (serous, mucinous, etc.), look for microinvasion, and evaluate any implants. This final report is what makes the diagnosis. ecancer

18. Implant evaluation (if present)
    If small growths are seen on peritoneal surfaces, the pathologist classifies them as non-invasive vs invasive implants. Invasive implants behave more like cancer and worsen prognosis compared with non-invasive ones. Cancer.gov

19. Molecular testing (selected cases)
    Pathology labs may look for KRAS (often mucinous) or BRAF (often serous) mutations. This supports the diagnosis pathway, explains biology, and may help in research, but it is not required in every case. ScienceDirect+1

20. CEA with colon work-up when mucinous and suspicious
    If the mass looks mucinous and markers or imaging suggest a bowel source, doctors may add colonoscopy to rule out a metastasis to the ovary.

D) Electrodiagnostic tests

1. Electrodiagnostic tests (like EMG or nerve conduction studies) are not used to diagnose ovarian tumours. They test nerves and muscles, not ovaries. If you see an ECG (heart tracing) before surgery, that is only to check heart safety for anesthesia—not to diagnose BOT. There is no electrical test that identifies a borderline ovarian tumour.

E) Imaging tests (core of the pre-op work-up)

1. Transvaginal ultrasound (TVUS)
   First-line imaging. It shows if the mass is cystic or solid, the number of locules, papillary projections, septations, and internal echoes. Experienced sonographers can spot features that suggest borderline pathology (e.g., multiple small papillae without obvious solid invasive nodules). ecancer

2. IOTA / ADNEX model ultrasound risk assessment
   This validated tool uses ultrasound features (with or without CA-125) to estimate the probability of a benign tumour, borderline tumour, early cancer, advanced cancer, or a secondary metastasis.

Non-pharmacological treatments (therapies & other measures)

1. Specialist gynecologic oncology surgery
   Purpose: Remove the tumor completely and stage the disease.
   Mechanism: Careful removal of the affected ovary/cyst and evaluation of the abdomen/pelvis to check spread; this directly treats the disease and guides follow-up. Cancer.gov

2. Fertility-sparing surgery (FSS)
   Purpose: Preserve future fertility in selected younger patients.
   Mechanism: Surgeons remove just the involved ovary or cyst (e.g., unilateral salpingo-oophorectomy or cystectomy in selected cases) while staging properly, balancing cure with fertility. PMC+1

3. Comprehensive surgical staging
   Purpose: Accurately determine stage and reduce undertreatment.
   Mechanism: Visual inspection, peritoneal washings, omentum sampling, and biopsies to document where disease is or isn’t present; this informs prognosis and surveillance. Cancer.gov

4. Expert pathology review
   Purpose: Confirm borderline vs invasive disease and classify implants.
   Mechanism: Subspecialty pathologists apply WHO criteria and implant classification (non-invasive vs invasive), which changes management. ICCR+1

5. Active surveillance after surgery
   Purpose: Detect rare recurrences early without overtreatment.
   Mechanism: Scheduled exams and imaging as indicated, based on stage, type, and fertility plans; most patients do well with watchful follow-up. Cancer.gov

6. Imaging-guided follow-up (ultrasound/CT/MRI as needed)
   Purpose: Monitor the remaining ovary or abdomen after FSS or staging.
   Mechanism: Noninvasive imaging identifies new cysts, masses, or implants over time. Cancer.gov

7. Fertility counseling & reproductive planning
   Purpose: Align treatment with goals for pregnancy.
   Mechanism: Counseling before and after FSS about timing of conception and options if recurrence occurs. PMC

8. Genetic risk review (selected cases)
   Purpose: Identify uncommon hereditary risks and tailor care.
   Mechanism: While most BOTs are sporadic, clinicians assess family history; testing is considered if there are red flags for hereditary ovarian/breast cancer. Cancer.gov

9. Second-look surgical evaluation (selected complex cases)
   Purpose: Clarify extent when implants are suspected or pathology is uncertain.
   Mechanism: Additional operative assessment at referral centers helps finalize staging and remove residual disease when indicated. esgo.org

10. Pain management (non-opioid first)
    Purpose: Control pelvic discomfort without unnecessary drugs.
    Mechanism: Stepwise use of non-opioids, procedures when appropriate, and addressing causes (e.g., post-surgical adhesions). Cancer.gov

11. Management at specialist centers
    Purpose: Improve outcomes when implants or advanced stage present.
    Mechanism: Multidisciplinary care with surgeons, pathologists, and radiologists experienced in BOTs. esgo.org

12. Lifestyle & survivorship care
    Purpose: Support overall health and reduce long-term risks.
    Mechanism: Plant-forward diet, physical activity, and weight management per ACS/NCCN guidance improve energy, function, and general health after cancer-related treatment. ACS Publications+1

13. Nutrition optimization (treat or prevent malnutrition)
    Purpose: Maintain strength and recovery after surgery.
    Mechanism: Evidence-based clinical nutrition steps (adequate protein, calories, and micronutrients) tailored by a dietitian for cancer survivors. Espen

14. Pelvic floor physiotherapy (as needed)
    Purpose: Address pelvic pain or dysfunction after surgery.
    Mechanism: Targeted exercises and techniques to relax or strengthen muscles and improve comfort and sexual function. Cancer.gov

15. Psychosocial support and counseling
    Purpose: Reduce anxiety and improve coping.
    Mechanism: Structured counseling/support groups for survivorship stress, fertility concerns, and body-image issues. NCCN

16. Smoking cessation
    Purpose: Improve surgical recovery and long-term health.
    Mechanism: Stopping tobacco reduces complications and improves overall survival in cancer survivors. American Cancer Society

17. Sexual health counseling
    Purpose: Manage dyspareunia or libido changes post-surgery.
    Mechanism: Education, lubricants, pelvic PT, and referral to sexual-medicine specialists when needed. NCCN

18. Vaccinations & preventive care
    Purpose: Keep routine health maintenance on track.
    Mechanism: Following survivorship guidelines for immunizations and screening helps overall outcomes. JNCCN

19. Return-to-activity planning
    Purpose: Safely resume exercise/work after surgery.
    Mechanism: Gradual, supervised increase in activity improves fitness and quality of life. JNCCN

20. Clear follow-up schedule written plan
    Purpose: Ensure you know when to come back and what to watch for.
    Mechanism: A survivorship plan listing visit frequency, warning signs, and points of contact. NCCN

---

Drug treatments

Important upfront truth: There are no FDA-approved medicines specifically for borderline ovarian tumors, and major evidence reviews report no proven survival benefit from routine chemotherapy or hormone therapy in typical BOT. Drug treatment may be considered only in unusual scenarios (e.g., invasive implants, progression toward low-grade serous carcinoma, or rare advanced disease) and is off-label for BOT. Decisions must be individualized at specialist centers. Below are drugs approved for epithelial ovarian cancer (or other cancers) whose labels are cited for mechanism/dosing information; their use in BOT, if any, is exceptional and off-label. PMC+1

1. Carboplatin (PARAPLATIN)
   Class: Platinum. Typical label dosing: AUC-based dosing (e.g., AUC 5–7.5 q3–4 weeks) under specialist supervision. Purpose (context): Backbone agent for epithelial ovarian cancer; rarely considered if BOT behaves like invasive disease. Mechanism: Cross-links DNA to stop cell division. Key side effects: Myelosuppression, nausea, nephrotoxicity (less than cisplatin), hypersensitivity with repeated exposure. FDA Access Data

2. Paclitaxel (Taxol)
   Class: Taxane. Dose (label examples): 175 mg/m² IV over 3 h every 3 weeks (varies by regimen). Purpose: Pairs with platinum in epithelial ovarian cancer; off-label if BOT transforms/behaves invasively. Mechanism: Stabilizes microtubules, blocking mitosis. Side effects: Neutropenia, neuropathy, alopecia, hypersensitivity reactions (premedication required). FDA Access Data

3. Paclitaxel protein-bound (Abraxane)
   Class: Taxane. Dose: See label; albumin-bound formulation may alter hypersensitivity risk. Purpose/Mechanism: As above; microtubule stabilization. Side effects: Myelosuppression, neuropathy, fatigue. FDA Access Data

4. Bevacizumab (Avastin)
   Class: Anti-VEGF antibody. Dose: Common ovarian regimens ~15 mg/kg q3w with chemo then maintenance (per label for epithelial ovarian cancer contexts). Purpose: Anti-angiogenic therapy for invasive epithelial ovarian cancer; not standard for BOT and caution is needed in ovarian disease with bowel involvement. Mechanism: Blocks VEGF to starve tumor blood supply. Key risks: GI perforation/fistula, hypertension, bleeding. FDA Access Data

5. Olaparib (Lynparza)
   Class: PARP inhibitor. Dose: 300 mg orally twice daily (tablet, per label indications). Purpose: Maintenance/therapy in BRCA-mutated epithelial ovarian cancer—not BOT. Mechanism: Inhibits PARP to exploit homologous recombination deficiency. Side effects: Anemia, fatigue, nausea, rare MDS/AML. FDA Access Data

6. Niraparib (Zejula)
   Class: PARP inhibitor. Dose: Individualized starting dose by weight/platelets; oral daily maintenance in EOC per label. Purpose: Maintenance after platinum response in EOC—not BOT. Mechanism: PARP inhibition; impairs DNA repair. Side effects: Thrombocytopenia, anemia, hypertension. FDA Access Data

7. Cisplatin
   Class: Platinum. Dose: Various IV schedules; more nephrotoxic/emetic than carboplatin. Purpose: Historical platinum in EOC; rarely relevant to BOT except exceptional invasive scenarios. Mechanism/side effects: DNA cross-linking; nephrotoxicity, ototoxicity, neuropathy, emesis. FDA Access Data

8. Docetaxel
   Class: Taxane. Dose: Regimens vary (often 60–75 mg/m² q3w in EOC combos). Purpose: Alternative to paclitaxel in EOC settings; not standard for BOT. Mechanism: Microtubule stabilization. Side effects: Neutropenia, edema, neuropathy. FDA Access Data

9. Letrozole (off-label context)
   Class: Aromatase inhibitor (breast label). Purpose: Sometimes tried in hormone-receptor–positive, low-grade serous disease; not approved for BOT. Mechanism: Lowers estrogen production. Side effects: Arthralgia, hot flashes, bone loss. PMC

10. Tamoxifen (off-label context)
    Class: SERM (breast label). Purpose: Occasionally used off-label in estrogen-receptor–positive ovarian neoplasms; not proven in BOT. Mechanism: Blocks estrogen receptor signaling. Side effects: Hot flashes, rare thromboembolism/endometrial risks. PMC

11. Rucaparib
    Class: PARP inhibitor (ovarian indications on label history vary by update). Purpose: EOC settings; not BOT. Mechanism/side effects: As other PARP inhibitors. FDA Access Data

12. Topotecan
    Class: Topoisomerase I inhibitor (EOC label). Purpose: Recurrent EOC; not BOT. Mechanism: DNA damage via topo-I inhibition. Side effects: Myelosuppression. FDA Access Data

13. Pegylated liposomal doxorubicin
    Class: Anthracycline (EOC label). Purpose: Recurrent EOC, not BOT. Mechanism: DNA intercalation/free-radical damage. Side effects: Hand-foot syndrome, mucositis, myelosuppression. FDA Access Data

14. Gemcitabine
    Class: Antimetabolite (used in EOC regimens). Mechanism: Nucleoside analog inhibiting DNA synthesis. Side effects: Myelosuppression, fatigue. FDA Access Data

15. Cyclophosphamide
    Class: Alkylator. Mechanism: DNA cross-linking. Use: Historical EOC regimens; not BOT. Side effects: Myelosuppression, cystitis (hydrate/mesna as needed). FDA Access Data

16. Pemetrexed (limited EOC use off-label)
    Class: Antifolate. Mechanism: Inhibits folate-dependent enzymes in DNA synthesis. Side effects: Myelosuppression, mucositis (folate/B12 required). FDA Access Data

17. Pembrolizumab (tissue-agnostic MSI-H/TMB-high)
    Class: PD-1 inhibitor. Purpose: Rare consideration if a tumor is MSI-H/dMMR; BOT rarely fits this. Mechanism: Unleashes T-cell response. Side effects: Immune-related events. FDA Access Data

18. Avelumab/other checkpoint inhibitors (selected indications)
    Purpose/Mechanism: Immunotherapy for specific biomarker-defined settings; not standard for BOT. Risk: Immune toxicities. FDA Access Data

19. Trametinib/MEK inhibitors (for low-grade serous carcinoma, not BOT)
    Note: Included only to clarify boundaries—approved/used in LGS carcinoma in trials/labels, not borderline tumors. Mechanism: MEK inhibition of MAPK pathway. annalsofoncology.org

20. Any systemic therapy for BOT
    Bottom line: Not routinely recommended; decisions are case-by-case at expert centers when pathology shows invasive implants or transformation. PMC

---

Dietary molecular supplements

Important: No supplement treats or cures borderline ovarian tumors. Use supplements only to correct deficiencies or for survivorship well-being, ideally with a dietitian. Guidance below aligns with ACS/NCCN survivorship nutrition principles. ACS Publications+1

1. Vitamin D (correct deficiency)
   Dose: Per lab-guided repletion/maintenance.
   Function: Bone/muscle health and general well-being during survivorship.
   Mechanism: Regulates calcium and immune signaling; deficiency is common post-treatment/surgery. Espen

2. Calcium (if dietary intake is low)
   Dose: Fill the gap to ~1000–1200 mg/day from food + supplement.
   Function: Bone health, especially if ovarian hormones are reduced.
   Mechanism: Mineral for bone remodeling; pair with Vitamin D. Espen

3. Omega-3 fatty acids (fish oil or diet)
   Dose: Food-first (fatty fish 2×/week) or supplement if advised.
   Function: May help general cardiometabolic health and inflammation balance.
   Mechanism: EPA/DHA modulate eicosanoids and membrane signaling. ACS Publications

4. Fiber (psyllium or food-based)
   Dose: Aim 25–30 g/day, supplement only if diet falls short.
   Function: Bowel regularity, microbiome support.
   Mechanism: Increases stool bulk/short-chain fatty acid production. ACS Publications

5. Protein supplements (whey/plant) if intake inadequate
   Dose: To reach daily protein targets (often 1.0–1.2 g/kg/day in survivorship if appropriate).
   Function: Maintain lean mass after surgery.
   Mechanism: Supplies essential amino acids for repair. Espen

6. Iron (only if iron-deficiency anemia is proven)
   Dose: Lab-guided; avoid unnecessary iron.
   Function: Corrects anemia-related fatigue.
   Mechanism: Restores hemoglobin/iron stores. Espen

7. Vitamin B12 (if low)
   Dose: Lab-guided oral or injection.
   Function: Neurologic/hematologic health.
   Mechanism: Cofactor in DNA synthesis and myelin integrity. Espen

8. Folate (diet-first; supplement only if deficient)
   Dose: As required by labs/dietitian.
   Function: Supports hematologic health.
   Mechanism: One-carbon metabolism for DNA synthesis. Espen

9. Magnesium (if low)
   Dose: Replace to normal range.
   Function: Muscle/nerve function; may help cramps after surgery.
   Mechanism: Cofactor for hundreds of enzymes. Espen

10. Probiotics (selected cases)
    Dose: Short courses with clinician guidance.
    Function: Manage antibiotic-associated diarrhea or GI upset.
    Mechanism: Modulate gut microbiota; strain-specific effects. Espen

---

Drugs for immunity booster / regenerative / stem-cell

There are no approved “immune-booster” or stem-cell drugs for borderline ovarian tumors. Using such products outside clinical trials is not recommended. Below are concepts sometimes discussed in survivorship care; they are not treatments for BOT. JNCCN

1. Seasonal vaccines (e.g., influenza, COVID-19 per guidelines)
   Dose: Per public health schedule.
   Function/Mechanism: Prime adaptive immunity to prevent infections during recovery. JNCCN

2. Vitamin D repletion (if deficient)
   Dose: As above.
   Function/Mechanism: Supports normal immune signaling; not cancer therapy. Espen

3. Physical activity “as medicine”
   Dose: Gradual build toward ACS/NCCN targets.
   Function/Mechanism: Trains innate/adaptive responses and lowers inflammation; improves strength and fatigue. ACS Publications

4. Nutrition therapy for malnutrition
   Dose: Individual plan.
   Function/Mechanism: Restores immune competence via adequate protein, micronutrients, and energy. Espen

5. Smoking cessation
   Dose: Behavioral + pharmacologic aids as indicated.
   Function/Mechanism: Reduces chronic inflammation and infection risk; improves surgical healing. American Cancer Society

6. Clinical trials (cellular or novel immunotherapies)
   Dose: Per protocol only.
   Function/Mechanism: Research settings explore immune or regenerative approaches; not standard for BOT. Cancer.gov

---

Surgeries (what is done and why)

1. Cystectomy (carefully selected cases)
   What/Why: Remove only the cyst while preserving ovarian tissue—used cautiously (particularly in serous; less favored in mucinous due to higher recurrence). Aim is fertility preservation with proper staging. ecancer

2. Unilateral salpingo-oophorectomy (USO)
   What/Why: Remove one ovary and tube when disease is limited to one side; common fertility-sparing option. Provides excellent control with preserved fertility potential. PMC

3. Bilateral salpingo-oophorectomy (BSO)
   What/Why: Remove both ovaries and tubes when childbearing is complete or disease/risks are bilateral. Reduces recurrence risk and removes the main disease site. Cancer.gov

4. Omentectomy and peritoneal biopsies (staging)
   What/Why: Sample/remove omentum and take biopsies to detect implants; accurate staging drives prognosis and follow-up. Cancer.gov

5. Resection of peritoneal implants (specialist centers)
   What/Why: Remove visible implants and distinguish non-invasive vs invasive; management differs, and expert review is advised. esgo.org

---

Preventions

No step fully prevents BOT, but healthy living supports overall gynecologic health.

1. Maintain healthy body weight and stay active (ACS). ACS Publications

2. Eat a plant-forward diet rich in vegetables, fruits, whole grains, legumes, and nuts (ACS/NCCN). ACS Publications+1

3. Do not smoke; seek help to quit. American Cancer Society

4. Attend regular gynecologic checkups; evaluate new/persistent pelvic symptoms promptly. Cancer.gov

5. Discuss family history; consider genetics referral if patterns suggest hereditary risk. Cancer.gov

6. Use talc-free perineal hygiene products (precautionary approach). ACS Publications

7. Manage metabolic conditions (e.g., diabetes) with your clinician. JNCCN

8. Consider timely childbearing and avoid unnecessary long-term hormone therapies without medical indication (individualized). Cancer.gov

9. Get recommended vaccines to reduce infection-related surgical risks. JNCCN

10. Seek care at centers experienced with BOT for accurate diagnosis and staging. esgo.org

---

When to see a doctor

See a gynecologist or gynecologic oncologist now if you have persistent pelvic/abdominal pain, bloating, early fullness while eating, menstrual changes, a new pelvic mass on imaging, or post-surgical new symptoms (fever, severe pain, heavy bleeding). Also return for any new or worsening symptoms during surveillance, or if you plan pregnancy after fertility-sparing surgery and need timing guidance. Cancer.gov

---

Foods to emphasize and to limit

Eat more of (focus foods):

1. Vegetables (aim diverse colors, daily) and fruits (daily).
2. Whole grains (oats, brown rice, whole-wheat).
3. Legumes (beans, lentils) and nuts/seeds.
4. Lean proteins including fish (especially fatty fish twice weekly).
5.  Fermented dairy/yogurt if tolerated. ACS Publications+1

Limit/avoid:

1. Processed meats and excess red meat;
2. Sugary drinks and ultra-processed snacks;
3. Excess alcohol;
4. Very high-salt, deep-fried foods;
5. Mega-dose supplements not prescribed for a proven deficiency. ACS Publications

---

Frequently asked questions (FAQs)

1) Is a borderline ovarian tumor cancer?
It is not invasive cancer; it is an abnormal growth with very low malignant potential. Most people do extremely well after surgery. Cancer.gov

2) What is the usual treatment?
Surgery with proper staging; many patients need no chemotherapy. Cancer.gov

3) Can I keep my fertility?
Often yes—fertility-sparing surgery is widely accepted for carefully selected patients. PMC

4) What is the prognosis?
Excellent: long-term survival is very high, especially for early-stage disease. Cancer.gov

5) Will I need chemotherapy?
Usually no. Evidence hasn’t shown survival benefit for typical BOT; it’s reserved for unusual cases. PMC

6) What follow-up do I need?
Regular exams and imaging as advised, especially after fertility-sparing surgery. Cancer.gov

7) What are “implants”?
Small deposits of tumor on peritoneal surfaces; classified as non-invasive or invasive, which affects management. ICCR

8) Are mucinous and serous borderline tumors managed the same?
Principles overlap, but mucinous cystectomy is less favored due to higher recurrence risk; surgery choice is individualized. ecancer

9) Should I seek a second opinion on the pathology?
Yes—expert pathology can change decisions, especially with implants. esgo.org

10) Can diet or supplements cure it?
No. Diet supports recovery and overall health but doesn’t replace surgery. ACS Publications

11) Do hormones affect these tumors?
Some are ER-positive, but routine hormone therapy hasn’t shown benefit in BOT. PMC

12) What if I get pregnant after FSS?
Many conceive successfully; coordinate timing and surveillance with your surgeon and OB-GYN. PMC

13) What warning signs of recurrence should I watch for?
New pelvic pain, bloating, or persistent masses—report promptly. Cancer.gov

14) Are PARP inhibitors for me?
They’re for epithelial ovarian cancer indications, not standard for BOT. FDA Access Data+1

15) Where should I be treated?
Preferably at a center with experience in gynecologic oncology and BOT. esgo.org

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 30, 2025.